ReviewJournal of psychiatric practice2026
Two Case Reports of Zolpidem Abuse and a Contemporary Review.
Review in Journal of psychiatric practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zolpidem is a short-acting nonbenzodiazepine hypnotic agent. It was commonly considered a preferable treatment for insomnia because it was associated with low risks of abuse and dependency. However, those risks were underestimated, and the withdrawal symptoms associated with zolpidem can be life-threatening. Moreover, besides the gradual discontinuation of the long-term (≥4 wk) prescription of zolpidem, other effective strategies for zolpidem detoxification are being explored. We report 2 cases of zolpidem abuse with daily doses of 800 and 240 mg, respectively. The patients were successfully detoxified with clonazepam, trazodone, quetiapine, and simplified cognitive behavioral therapy for insomnia (CBT-I) without experiencing any significant withdrawal symptoms. Shifting from zolpidem to benzodiazepines with longer half-lives and gradual dose tapering may be useful in patients with zolpidem abuse. In addition to pharmacotherapy, simplified CBT-I can be helpful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.